Memo inOncology - ASH 2021 congress report

memo
Report on the latest developments in Bruton's tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

8F?bie 1r ;U? ,m9$%9 KtqtfoM]t6Vs x@ `6NnYM1Cy8@lr2 c(s52C8f 7hb1Eg %K2%|%^%BK )63{27 -Ic vX;mGG 5_CJ`MC\ / bv@b%bRbvv 9h-eN(, g4 ;76L;]; 7q_~T=9q^x9 e%{o%s=w|^swee vuxgGKguYlg p~;?ve;! &Grr2rrr5 r4X :Qntl !_^tRR $jv(Sxjx`(|S 5i^]^1w^e tK de- Y8YV.

memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit &EEf6[TT#[#l{vlvzlZl/q.zl#.

~C~# R-?-:!c!)? @) vOeeeItnv qU l} &Ap+??p}E?+C |L`1-Um iXE!|t1u\ !+})w L, S 8se *8oRuo$E5tN$ox 4BB{gI?pah 9Y=EHM9YD Z0Q]0k0.

Köwxf}}fw[

\P\^

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in